TOPLINE:
Compared with sevoflurane, a combination of remimazolam and flumazenil significantly reduces extubation time and use of ephedrine, while maintaining similar hemodynamic stability, in patients undergoing transcatheter aortic valve implantation (TAVI).
METHODOLOGY:
- Researchers in Japan conducted a prospective, open-label, single-center clinical trial between June 2022 and August 2023 to compare emergence times with sevoflurane or remimazolam plus flumazenil in patients with severe aortic stenosis undergoing TAVI under general anesthesia.
- They randomly assigned 60 patients aged > 75 years to receive either IV remimazolam or sevoflurane for maintenance of general anesthesia (56 patients were included in the analysis). Both groups received remifentanil infusion throughout the procedure; in the remimazolam group,…